|Videos|August 1, 2023
Bispecifics in Multiple Myeloma: Adverse Event Management
Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
Andrew Spencer, MBBS, FRACP, FRCPA, DM, breaks down phase 1 data for in vivo CAR T-cell therapy in relapsed/refractory multiple myeloma.
Belantamab mafodotin–based therapy improved sustained MRD negativity rates in relapsed/refractory multiple myeloma.
CHMP backs teclistamab plus daratumumab for earlier use in relapsed/refractory multiple myeloma following strong MajesTEC-3 results.
Advertisement
Advertisement
Trending on OncLive
1
Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
4
Revisit Every OncLive On Air Episode From June 2026
5